Please use this identifier to cite or link to this item: http://buratest.brunel.ac.uk/handle/2438/5703
Title: Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway
Authors: Orton, RJ
Adriaens, ME
Gormand, A
Sturm, OE
Kolch, W
Gilbert, D
Issue Date: 2009
Publisher: BioMed Central
Citation: BMC Systems Biology, 3: 100, Oct 2009
Abstract: BACKGROUND: The Epidermal Growth Factor Receptor (EGFR) activated Extracellular-signal Regulated Kinase (ERK) pathway is a critical cell signalling pathway that relays the signal for a cell to proliferate from the plasma membrane to the nucleus. Deregulation of the EGFR/ERK pathway due to alterations affecting the expression or function of a number of pathway components has long been associated with numerous forms of cancer. Under normal conditions, Epidermal Growth Factor (EGF) stimulates a rapid but transient activation of ERK as the signal is rapidly shutdown. Whereas, under cancerous mutation conditions the ERK signal cannot be shutdown and is sustained resulting in the constitutive activation of ERK and continual cell proliferation. In this study, we have used computational modelling techniques to investigate what effects various cancerous alterations have on the signalling flow through the ERK pathway. RESULTS: We have generated a new model of the EGFR activated ERK pathway, which was verified by our own experimental data. We then altered our model to represent various cancerous situations such as Ras, B-Raf and EGFR mutations, as well as EGFR overexpression. Analysis of the models showed that different cancerous situations resulted in different signalling patterns through the ERK pathway, especially when compared to the normal EGF signal pattern. Our model predicts that cancerous EGFR mutation and overexpression signals almost exclusively via the Rap1 pathway, predicting that this pathway is the best target for drugs. Furthermore, our model also highlights the importance of receptor degradation in normal and cancerous EGFR signalling, and suggests that receptor degradation is a key difference between the signalling from the EGF and Nerve Growth Factor (NGF) receptors. CONCLUSION: Our results suggest that different routes to ERK activation are being utilised in different cancerous situations which therefore has interesting implications for drug selection strategies. We also conducted a comparison of the critical differences between signalling from different growth factor receptors (namely EGFR, mutated EGFR, NGF, and Insulin) with our results suggesting the difference between the systems are large scale and can be attributed to the presence/absence of entire pathways rather than subtle difference in individual rate constants between the systems.
Description: This article has been made available through the Brunel Open Access Publishing Fund - Copyright @ 2009 Orton et al.
URI: http://bura.brunel.ac.uk/handle/2438/5703
DOI: http://dx.doi.org/10.1186/1752-0509-3-100
ISSN: 1752-0509
Appears in Collections:Publications
Computer Science
Dept of Computer Science Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf2.53 MBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.